The FDA decision on Aclaris Therapeutics Inc.’s (ACRS) New Drug Application for A-101 40% topical solution, proposed for the treatment of seborrheic keratosis, is expected on December 24, 2017.A-101 40% topical solution is a proprietary, high-concentration hydrogen peroxide formulation, and is designed to work by penetrating into the seborrheic keratosis (SK) lesion and causing oxidative damage, which can ultimately lead to shedding of the SK cells.The Company has sought approval of A-101 40% topical solution in the European Union too, and a Marketing Authorization Application in this regard was submitted in August of this year.ACRS closed Tuesday’s (Nov.28) trading at $23.03, down 1.24%.